165 related articles for article (PubMed ID: 25809175)
21. Facilitated bone mineral density testing versus hospital-based case management to improve osteoporosis treatment for hip fracture patients: additional results from a randomized trial.
Morrish DW; Beaupre LA; Bell NR; Cinats JG; Hanley DA; Harley CH; Juby AG; Lier DA; Maksymowych WP; Majumdar SR
Arthritis Rheum; 2009 Feb; 61(2):209-15. PubMed ID: 19177538
[TBL] [Abstract][Full Text] [Related]
22. Cost of care for seniors hospitalized for hip fracture and related procedures.
Titler M; Dochterman J; Kim T; Kanak M; Shever L; Picone DM; Everett L; Budreau G
Nurs Outlook; 2007; 55(1):5-14. PubMed ID: 17289462
[TBL] [Abstract][Full Text] [Related]
23. Incidence and costs of osteoporosis-associated hip fractures in Austria.
Koeck CM; Schwappach DL; Niemann FM; Strassmann TJ; Ebner H; Klaushofer K
Wien Klin Wochenschr; 2001 May; 113(10):371-7. PubMed ID: 11432126
[TBL] [Abstract][Full Text] [Related]
24. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
Cotté FE; Mercier F; De Pouvourville G
Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
26. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial.
Majumdar SR; Beaupre LA; Harley CH; Hanley DA; Lier DA; Juby AG; Maksymowych WP; Cinats JG; Bell NR; Morrish DW
Arch Intern Med; 2007 Oct; 167(19):2110-5. PubMed ID: 17954806
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women.
Nagata-Kobayashi S; Shimbo T; Fukui T
J Bone Miner Metab; 2002; 20(6):350-7. PubMed ID: 12434163
[TBL] [Abstract][Full Text] [Related]
28. The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system.
Solomon DH; Patrick AR; Schousboe J; Losina E
J Bone Miner Res; 2014 Jul; 29(7):1667-74. PubMed ID: 24443384
[TBL] [Abstract][Full Text] [Related]
29. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.
Kingkaew P; Maleewong U; Ngarmukos C; Teerawattananon Y
Value Health; 2012; 15(1 Suppl):S20-8. PubMed ID: 22265062
[TBL] [Abstract][Full Text] [Related]
30. Making the most of managed care dollars spent for postmenopausal osteoporosis.
Ettinger B
Manag Care Interface; 2005 Dec; 18(12):55-9. PubMed ID: 16405226
[TBL] [Abstract][Full Text] [Related]
31. Cost-avoidance and qualitative analysis of clinical pharmacy interventions by psychiatric pharmacy residents at state psychiatric facilities.
Gardner KN; Diefenderfer LA; Nelson LA; Iuppa C; Elliott E; Kleinhesselink K; Sass D; Sommi RW
Am J Health Syst Pharm; 2016 Jan; 73(1):e46-53. PubMed ID: 26683680
[TBL] [Abstract][Full Text] [Related]
32. The cost of treating osteoporotic fractures in the United Kingdom female population.
Dolan P; Torgerson DJ
Osteoporos Int; 1998; 8(6):611-7. PubMed ID: 10326069
[TBL] [Abstract][Full Text] [Related]
33. Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom.
Gutiérrez L; Roskell N; Castellsague J; Beard S; Rycroft C; Abeysinghe S; Shannon P; Gitlin M; Robbins S
Bone; 2012 Sep; 51(3):324-31. PubMed ID: 22684000
[TBL] [Abstract][Full Text] [Related]
34. The socioeconomic burden of fractures: today and in the 21st century.
Johnell O
Am J Med; 1997 Aug; 103(2A):20S-25S; discussion 25S-26S. PubMed ID: 9302894
[TBL] [Abstract][Full Text] [Related]
35. $1.8 Million and counting: how volatile agent education has decreased our spending $1000 per day.
Miller SA; Aschenbrenner CA; Traunero JR; Bauman LA; Lobell SS; Kelly JS; Reynolds JE
J Clin Anesth; 2016 Dec; 35():253-258. PubMed ID: 27871537
[TBL] [Abstract][Full Text] [Related]
36. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy.
Visentin P; Ciravegna R; Fabris F
Maturitas; 1997 Apr; 26(3):185-92. PubMed ID: 9147350
[TBL] [Abstract][Full Text] [Related]
37. Description and financial impact of ambulatory care pharmacy team interventions within an underserved patient population.
Hasham S; Moye-Dickerson P; Thurston MM
Am J Health Syst Pharm; 2023 Feb; 80(Suppl 1):S42-S48. PubMed ID: 36371741
[TBL] [Abstract][Full Text] [Related]
38. Economic effects of clinical pharmacy interventions: a literature review.
De Rijdt T; Willems L; Simoens S
Am J Health Syst Pharm; 2008 Jun; 65(12):1161-72. PubMed ID: 18541687
[TBL] [Abstract][Full Text] [Related]
39. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years.
Newman ED; Ayoub WT; Starkey RH; Diehl JM; Wood GC
Osteoporos Int; 2003 Apr; 14(2):146-51. PubMed ID: 12730773
[TBL] [Abstract][Full Text] [Related]
40. Implementation of a drug therapy monitoring clinic in a primary-care setting.
Yanchick JK
Am J Health Syst Pharm; 2000 Dec; 57 Suppl 4():S30-4. PubMed ID: 11148942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
